Arch Therapeutics Archives - Framingham Source

Arch Therapeutics $2.8 Million Registered Direct Offering

May 13, 2019May 14, 2019 Framingham Source Editor Susan Petroni 364 Views 0 Comments Arch Therapeutics, Stock offering

8 Shares

The following is a press release. FRAMINGHAM – Arch Therapeutics, Inc., a developer of novel liquid, gel and solid hemostatic

Read more

Business Health

Framingham Company Gets Government Clearance For Gel To Treat Wounds

December 17, 2018December 18, 2018 Framingham Source Editor Susan Petroni 64 Views 0 Comments AC5™ Topical Gel, Arch Therapeutics, Inc., U.S. Food and Drug Administration (FDA)

5 Shares

FRAMINGHAM – Arch Therapeutics, Inc., developer of novel liquid, gel and solid hemostatic and wound care devices, today, Dec. 17,

Read more

Framingham Company Submits Topical Gel for Wounds to FDA For Approval

July 25, 2017July 25, 2017 Framingham Source Editor Susan Petroni 32 Views 0 Comments AC5™ Topical Gel, Arch Therapeutics, U.S. Food and Drug Administration

9 Shares

FRAMINGHAM – Arch Therapeutics, Inc., a developer of novel liquid, gel and solid hemostatic and wound care devices, today, July 25,

Read more

Framingham-Based Medical Device Company Offering $6.1 Million Stock Sale

February 21, 2017February 21, 2017 Framingham Source Editor Susan Petroni 19 Views 0 Comments Arch Therapeutics, Massachusetts Life Science, Stock offering

1 Shares

FRAMINGHAM – Arch Therapeutics, Inc. , a Framingham-based biotechnology company that develops products to stop bleeding and control leaking during surgery,

Read more